Saturday, October 3, 2026

USD/JPY Over 1% Down In The Last 24 Hours

USD/JPY Over 1% Down In The Last 24 Hours

(VIANEWS) - USD/JPY (USDJPY) has been up by 1.9323% for the last session's close. At 17:06 EST on Wednesday, 1 May, USD/JPY (USDJPY) is $154.65.

USD/JPY (USDJPY) Range

Regarding USD/JPY's daily highs and lows, it's 1.897% down from its trailing 24 hours low of $157.64 and 2.004% down from its trailing 24 hours high of $157.81.

USD/JPY's yearly highs and lows, it's 15.681% up from its 52-week low and 3.321% down from its 52-week high.

Volatility

USD/JPY's last week, last month's, and last quarter's current intraday variation average was 0.37%, 0.16%, and 0.33%, respectively.

USD/JPY's highest amplitude of average volatility was 0.89% (last week), 0.34% (last month), and 0.33% (last quarter), respectively.

Previous days news about USD/JPY (USDJPY)

  • Usd/jpy finds support near 155.00 after plunging due to probable Japan’s intervention. According to FXStreet on Monday, 29 April, "The USD/JPY findsprovisional support near 155.00 in Monday's early American session. "
  • Usd/jpy recovers as traders buy the dip. According to FXStreet on Tuesday, 30 April, "USD/JPY peaked at a 34-year high of 160.32 on Monday but then rolled over and fell following a rumored currency intervention by the Japanese authorities who have been warning about the Yen weakening excessively ever since USD/JPY rose above 150.00 in March.", "This in turn is likely to continue pressuring gains in USD/JPY regardless of whether the Japanese authorities intervene. "

More news about USD/JPY (USDJPY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com